Compare AMS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMS | AKTX |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 11.5M |
| IPO Year | 1995 | 2014 |
| Metric | AMS | AKTX |
|---|---|---|
| Price | $1.82 | $0.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.53 |
| AVG Volume (30 Days) | 3.8K | ★ 348.3K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 230.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,714,000.00 | N/A |
| Revenue This Year | $3.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $1.79 | $0.13 |
| 52 Week High | $3.11 | $1.58 |
| Indicator | AMS | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 23.83 | 25.67 |
| Support Level | N/A | N/A |
| Resistance Level | $2.19 | $0.27 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 7.35 | 0.32 |
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.